


# Inflammasomes in Neurological Disorders



## Inflammasome Structure and Complexes

### Inflammasome sensors




### Adaptor



### Effector




### Inflammasome complex formation




### Inflammasome-related Antibodies

<p><b>NLRP2/NALP2 antibody [N3C2]</b> Internal (GTx6310888)</p>	<p><b>NLRP3 antibody [HL2813]</b> (GTx6399594)</p>	<p><b>Caspase 1 antibody [HL2005]</b> (GTx637906)</p>	<p><b>Gasdermin D antibody [HL1334]</b> (GTx636754)</p>	<p><b>IKK alpha antibody [GTx132964]</b></p>	<p><b>IKK beta antibody [GTx107970]</b></p>
<p><b>IKK gamma antibody [HL1577]</b> (GTx637052)</p>	<p><b>NFκB p65 antibody [GTx107678]</b></p>	<p><b>NFκB p105 antibody [HL1784]</b> (GTx637436)</p>	<p><b>IL1 beta antibody [HL1421]</b> (GTx636887)</p>	<p><b>IL18 antibody [HL1761]</b></p>	<p><b>IL18 antibody [HL1859]</b></p>
<p><b>IL17A antibody [HL1421]</b> (GTx636887)</p>		<p><b>IL18 antibody [HL1761]</b></p>		<p><b>TLR2 antibody [N1N2], N-term</b> (GTx102357)</p>	


### Alzheimer's Disease (AD)



### Amotrophic Lateral Sclerosis (ALS)



### Epilepsy



### Alzheimer's disease

- Amyloid β<sub>1-42</sub>
- Hyperphosphorylated tau

### Misfolded or aggregated proteins

- Amyloid β
- SOD1 mutant
- α-Synuclein
- PrPSc
- TDP43

### Amotrophic lateral sclerosis

- Mutant SOD1
- TDP43 aggregates

### Epilepsy

- DAMPs resulting from mild seizure-related haemorrhages

### Multiple sclerosis

- DAMPs resulting from T-cell-mediated myelin damage

### Parkinson's disease

- α-Synuclein
- Impaired mitophagy

### Sepsis

- DAMPs resulting from pathogen-triggered neuroinflammation


### Stroke

- DAMPs resulting from ischaemic or haemorrhagic injury

### Traumatic brain injury

- DAMPs resulting from blunt force or penetrating injury


### Multiple Sclerosis (MS)





### Sepsis-associated Encephalopathy



### Stroke



### Traumatic Brain Injury (TBI)



- Citation Support
- Orthogonal Validation
- KO/KD Validation
- Protein Overexpression
- Comparable Abs
- Recombinant
- IP/MS Analysis
- HistoMAX

References:  
 1. *EMBO Mol Med.* 2019 Jun;11(6):e10248.  
 2. *Nat Rev Neurol.* 2024 Feb;20(2):67-83.